Jason Bednar

“Maybe as a follow-up just to one of the prior questions on next steps, can you talk about how you're currently thinking about what a more robust trial would look like after this safety and feasibility study?”

“I wanted to start actually on product sourcing. I appreciate the color on the $10 million in savings that you've already realized. It sounds like there's more to be had there.”

“Sorry to hammer here and beat a dead horse, but I'm going to ask another one on the D-stock. just a question on your confidence that this is just an America's issue that won't bleed over to EMEA and maybe talk about how America's is benchmarked versus EMEA.”

“Make sure I get the questions, and I'll add my congrats here on a nice quarter. The fact I'll start at the same place Jason Bedford did on infusion systems.”

“Afternoon and congrats on all the progress here, team. I wanted to start with the HIS announcement this afternoon. I have a few questions. I'm just going to pack them all in here.”